Literature DB >> 36216967

Oncological outcomes of cribriform histology pattern in prostate cancer patients: a systematic review and meta-analysis.

Giorgio Ivan Russo1, Timo Soeterik2, Ignacio Puche-Sanz3, Giuseppe Broggi4, Arturo Lo Giudice5, Cosimo De Nunzio6, Riccardo Lombardo6, Giancarlo Marra7, Giorgio Gandaglia8.   

Abstract

BACKGROUND: Changes applied to the Prostate cancer (PCa) histopathology grading, where patients with cribriform patterns (CP) may be categorized as grade group 2 and could hypothetically be surveilled. However, CP has been associated with worse oncological outcomes. The aim of our study is to systematically review and meta-analyze the available evidence on CP in PCa patients.
METHODS: This analysis was registered on PROSPERO (CRD42022298473). We performed a systematic literature search of PubMed, EMBASE and Scopus using Medical Subject Headings (MeSH) indexes, keyword searches, and publication types until December 2021. The search terms included: "prostate", "prostate cancer" and "cribriform". We also searched reference lists of relevant articles. Eligible studies included published journal articles that provided quantitative data on the association between cribriform patterns at radical prostatectomy and the presence of extra-prostatic extension (EPE), seminal vesicle invasion (SVI), positive surgical margins (PSM), biochemical recurrence (BCR) or cancer specific mortality (CSM).
RESULTS: Overall, 31 studies were included for the quantitative analysis. All articles have been published during a span of 11 years (2011-2022) with a mean month of follow-up of 62.87 months. The mean quality of these studies, assessed with the Newcastle Ottawa Scale was 6.27. We demonstrated that CP was associated with greater risk of EPE (odds ratio [OR] 1.96; P < 0.0001), SVI (OR: 2.89; p < 0.01), and PSM (OR: 1.88; p < 0.0007). Our analyses showed that CP was associated with greater risk of BCR (hazard ratio [HR]: 2.14; p < 0.01) and of CSM (HR: 3.30, p < 0.01).
CONCLUSION: The presence of CP is associated with adverse pathology at radical prostatectomy and worse biochemical recurrence and cancer specific mortality. These results highlight the importance of a better pathologic report of CP to advise clinician for a strict follow-up in PCa patients.
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Year:  2022        PMID: 36216967     DOI: 10.1038/s41391-022-00600-y

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.455


  36 in total

Review 1.  The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.

Authors:  Jonathan I Epstein; William C Allsbrook; Mahul B Amin; Lars L Egevad
Journal:  Am J Surg Pathol       Date:  2005-09       Impact factor: 6.394

2.  Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.

Authors:  Jonathan I Epstein; Mahul B Amin; Victor E Reuter; Peter A Humphrey
Journal:  Am J Surg Pathol       Date:  2017-04       Impact factor: 6.394

3.  Prognostic impact of intraductal carcinoma and large cribriform carcinoma architecture after prostatectomy in a contemporary cohort.

Authors:  Dominique Trudel; Michelle R Downes; Jenna Sykes; Ken J Kron; John Trachtenberg; Theodorus H van der Kwast
Journal:  Eur J Cancer       Date:  2014-04-03       Impact factor: 9.162

4.  True Incidence of Gleason 6 Pathology in Patients with Metastatic Castration Resistant Prostate Cancer (mCRPC).

Authors:  Alena Böker; Markus A Kuczyk; Mario W Kramer; Axel S Merseburger; Katharina Krüger; Florian Imkamp; Christoph A von Klot
Journal:  Adv Ther       Date:  2016-11-26       Impact factor: 3.845

5.  Prostatic ductal adenocarcinoma with cribriform architecture has worse prognostic features than non-cribriform-type.

Authors:  Sammy Au; Carlos F Villamil; Reza Alaghehbandan; Gang Wang
Journal:  Ann Diagn Pathol       Date:  2019-02-10       Impact factor: 2.090

6.  Cribriform growth is highly predictive for postoperative metastasis and disease-specific death in Gleason score 7 prostate cancer.

Authors:  Charlotte F Kweldam; Mark F Wildhagen; Ewout W Steyerberg; Chris H Bangma; Theodorus H van der Kwast; Geert J L H van Leenders
Journal:  Mod Pathol       Date:  2014-09-05       Impact factor: 7.842

7.  Survival rates of patients with prostatic cancer, tumor stage, and differentiation--preliminary report.

Authors:  J C Bailar; G T Mellinger; D F Gleason
Journal:  Cancer Chemother Rep       Date:  1966-03

8.  Genetic and Epigenetic Determinants of Aggressiveness in Cribriform Carcinoma of the Prostate.

Authors:  Habiba Elfandy; Joshua Armenia; Filippo Pederzoli; Eli Pullman; Nelma Pertega-Gomes; Nikolaus Schultz; Kartik Viswanathan; Aram Vosoughi; Mirjam Blattner; Konrad H Stopsack; Giorgia Zadra; Kathryn L Penney; Juan Miguel Mosquera; Svitlana Tyekucheva; Lorelei A Mucci; Christopher Barbieri; Massimo Loda
Journal:  Mol Cancer Res       Date:  2018-10-17       Impact factor: 5.852

9.  The PRISMA 2020 statement: An updated guideline for reporting systematic reviews.

Authors:  Matthew J Page; Joanne E McKenzie; Patrick M Bossuyt; Isabelle Boutron; Tammy C Hoffmann; Cynthia D Mulrow; Larissa Shamseer; Jennifer M Tetzlaff; Elie A Akl; Sue E Brennan; Roger Chou; Julie Glanville; Jeremy M Grimshaw; Asbjørn Hróbjartsson; Manoj M Lalu; Tianjing Li; Elizabeth W Loder; Evan Mayo-Wilson; Steve McDonald; Luke A McGuinness; Lesley A Stewart; James Thomas; Andrea C Tricco; Vivian A Welch; Penny Whiting; David Moher
Journal:  PLoS Med       Date:  2021-03-29       Impact factor: 11.069

10.  Large cribriform growth pattern identifies ISUP grade 2 prostate cancer at high risk for recurrence and metastasis.

Authors:  Eva Hollemans; Esther I Verhoef; Chris H Bangma; John Rietbergen; Jozien Helleman; Monique J Roobol; Geert J L H van Leenders
Journal:  Mod Pathol       Date:  2018-10-22       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.